Semaglutida Berberina

Retatrutide: Why the Triple Agonist Is 2026s Most Anticipated Weight Loss DrugRetatrutide: The Next Generation of Weight Loss Medication In 2026, the weight loss medication landscape is evolving rapidly. Retatrutide, developed by Eli Lilly, is the first triple agonist peptide — targeting three metabolic receptors simultaneously. How Retatrutide Compares Semaglutide (Ozempic/Wegovy): Single GLP-1 agonist → 15-17% weight loss Tirzepatide (Mounjaro/Zepbound): Dual GIP/GLP-1 agonist → 20-26% weight loss Retatrutide: Triple GIP/GLP-1/glucagon agonist → 24-28% weight loss Why Glucagon Matters The addition of glucagon receptor activation increases energy expenditure and promotes liver fat reduction — effects not seen with GLP-1 targeting alone. Read the complete retatrutide guide for dosing protocols and clinical data at glunovabio.com.